Related Experiment Video
Updated: Jan 18, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Resolve and regulate: Alum nanoplatform coordinating STING availability and agonist delivery for enhanced anti-tumor
Yu Sun1, Hideki Nakanishi2, Xiaonan Huang3
1Laboratory of Cell Glycobiology, School of Biotechnology and Key Laboratory of Carbohydrate Chemistry and Biotechnology of Ministry of Education, Jiangnan University, Wuxi, 214122, PR China; Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, PR China.
This study introduces DecG@Al, a novel platform that enhances STING pathway activation for cancer immunotherapy. It overcomes delivery and silencing barriers, leading to potent tumor suppression and improved survival.
Area of Science:
- Immunology
- Cancer Biology
- Nanotechnology
Background:
- The stimulator of interferon genes (STING) pathway is a key target in cancer immunotherapy.
- Clinical use of cyclic dinucleotide (CDN)-based STING agonists is limited by poor cytosolic delivery and tumor-specific STING silencing.
- Tumor STING silencing occurs via DNA methyltransferase-mediated promoter hypermethylation.
Purpose of the Study:
- To engineer a dual-action platform, DecG@Al, to overcome barriers hindering STING pathway activation in cancer.
- To combine aluminum hydroxide (Alum), 2'3'-cGAMP, and decitabine for enhanced CDN delivery and STING restoration.
- To evaluate the efficacy of DecG@Al in reprogramming the tumor microenvironment and suppressing tumor growth.
Main Methods:
- Developed DecG@Al, a platform integrating Alum, 2'3'-cGAMP, and decitabine.
- Assessed DecG@Al's ability to enhance transmembrane delivery of 2'3'-cGAMP and decitabine bioavailability.
- Utilized B16F10 melanoma models to evaluate immunomodulatory effects and tumor suppression.
Main Results:
- DecG@Al synergistically amplified intracellular CDN-STING complexes and STING pathway activation.
- DecG@Al reprogrammed the immunosuppressive tumor microenvironment, promoting M1 macrophages and activating dendritic cells.
- DecG@Al treatment led to potent tumor suppression, prolonged survival, and reduced CD8+ T cell exhaustion with minimal toxicity.
Conclusions:
- DecG@Al effectively addresses the root causes of insufficient CDN-STING complex formation.
- This clinically translatable strategy holds promise for reigniting antitumor immunity.
- DecG@Al offers a novel approach to enhance STING-based cancer immunotherapy.
